KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Deferred Taxes: 2021-2025

Historic Deferred Taxes for Castle Biosciences (CSTL) over the last 3 years, with Sep 2025 value amounting to $116,000.

  • Castle Biosciences' Deferred Taxes fell 97.79% to $116,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.6 million, marking a year-over-year decrease of 318.88%. This contributed to the annual value of $1.4 million for FY2024, which is 728.25% up from last year.
  • As of Q3 2025, Castle Biosciences' Deferred Taxes stood at $116,000, which was up 102.49% from -$4.7 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Deferred Taxes registered a high of $5.2 million during Q3 2024, and its lowest value of -$8.7 million during Q4 2021.
  • Over the past 3 years, Castle Biosciences' median Deferred Taxes value was -$503,000 (recorded in 2023), while the average stood at -$517,875.
  • As far as peak fluctuations go, Castle Biosciences' Deferred Taxes spiked by 99.57% in 2022, and later plummeted by 877.54% in 2024.
  • Quarterly analysis of 5 years shows Castle Biosciences' Deferred Taxes stood at -$8.7 million in 2021, then surged by 99.57% to -$38,000 in 2022, then plummeted by 521.05% to -$236,000 in 2023, then tumbled by 877.54% to -$2.3 million in 2024, then plummeted by 97.79% to $116,000 in 2025.
  • Its last three reported values are $116,000 in Q3 2025, -$4.7 million for Q2 2025, and -$770,000 during Q1 2025.